NICE IDs

03/07/2026

ID1627: Histamine dihydrochloride with interleukin-2 for maintenance treatment of acute myeloid leukaemia

26/06/2026

ID6575: Aficamten for treating symptomatic obstructive hypertrophic cardiomyopathy

19/06/2026

ID6597: Deuruxolitinib for treating severe alopecia areata

16/06/2026

ID6610: Cemiplimab for treating recurrent or metastatic cervical cancer that has progressed on or after platinum-based chemotherapy (review of TA901)

15/06/2026

ID6487: Glycopyrronium bromide cream for treating severe primary axillary hyperhidrosis

05/06/2026

ID6287: Sotorasib for previously treated KRAS G12C mutation-positive advanced non-small-cell lung cancer (MA review of TA781)

05/06/2026

ID6269: Pirtobrutinib for treating relapsed or refractory chronic lymphocytic leukaemia after a BTK inhibitor

02/06/2026

ID3843: Daratumumab with bortezomib, lenalidomide and dexamethasone for untreated multiple myeloma when a stem cell transplant is unsuitable

01/06/2026

ID6259: Teplizumab for delaying the onset of stage 3 type 1 diabetes in people 8 years and over with stage 2 type 1 diabetes

26/05/2026

ID6685: Cemiplimab with platinum-based chemotherapy for untreated advanced non-small-cell lung cancer (rapid review of TA1108)

19/05/2026

ID6615: Atogepant for treating migraine

14/05/2026

ID6195: Risdiplam for treating spinal muscular atrophy (review of TA755)

14/05/2026

ID6195: Nusinersen for treating spinal muscular atrophy (review of TA588)

13/05/2026

ID6578: Avapritinib for treating inadequately controlled moderate to severe indolent systemic mastocytosis

08/05/2026

ID6163: Sotatercept for treating pulmonary arterial hypertension

01/05/2026

ID6619: Lisocabtagene maraleucel for treating relapsed or refractory large B-cell lymphoma after 2 or more systemic treatments (review of TA987)

29/04/2026

ID6223: Osimertinib for maintenance treatment of EGFR mutation-positive unresectable locally advanced non-small-cell lung cancer after platinum-based chemoradiotherapy

29/04/2026

ID6323: Givinostat for treating Duchenne muscular dystrophy in people 6 years and over

27/04/2026

ID3753: Tisotumab vedotin for treating recurrent or metastatic cervical cancer that has progressed on or after systemic treatment

27/04/2026

ID6374: Durvalumab in combination for neoadjuvant and adjuvant treatment of resectable gastric and gastro-oesophageal junction cancer